<DOC>
	<DOCNO>NCT00592358</DOCNO>
	<brief_summary>This 8-week open-label trial , use daily dos paliperidone ( Invega ) treatment child adolescents meet DSM-IV criterion Bipolar I , Bipolar II , Bipolar Spectrum Disorder . Specific hypotheses follow : Hypothesis 1 : Bipolar Disorder symptomatology child adolescents DSM-IV Bipolar I , Bipolar II , Bipolar Spectrum Disorder responsive Invega treatment . Hypothesis 2 : Invega -associated improvement bipolar disorder symptomatology child adolescent translate improve functional capacity ( neuropsychological , social , occupational ) , well increase quality life throughout treatment . Hypothesis 2 : Invega treatment safe well tolerate reflect low drop rate absence major side effect .</brief_summary>
	<brief_title>Invega ( Paliperidone ) Treatment Mania Children Adolescents Ages 6-17 With Bipolar Disorder</brief_title>
	<detailed_description>Invega ( paliperidone ) , second generation antipsychotic ( SGA ) , psychotropic agent belong chemical class benzisoxazole derivative . Invega approve FDA treatment schizophrenia adult . Initial data suggest promising role Invega treatment bipolar disorder minimal adverse event weight gain . We propose study safety efficacy Invega therapy child adolescent Bipolar I , Bipolar II , Bipolar Spectrum Disorder . The study result use generate hypothesis large , randomize , control clinical trial explicit hypotheses sufficient statistical power . The propose study include 1 ) use 8-week design document response rate , 2 ) assessment impact Invega functional capacity ( quality life , psychosocial function ) cognition , 3 ) careful assessment safety tolerability .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<criteria>1 . Male female outpatient 617 year age ( inclusive ) . 2 . Subjects diagnosis Bipolar Bipolar Spectrum Disorder currently display manic , hypomanic , mixed symptom ( without psychotic feature ) , DSMIV , manifest clinical evaluation confirm structured interview . Bipolar Spectrum Disorder ( sub threshold bipolar disorder ) operationalized severe mood disturbance , meet DSMIV Criteria A bipolar disorder display few element Criteria B ( require 2 item elation category 3 irritability ) . 3 . Subjects must score ≥ 20 YMRS . 4 . Subjects legal representative must level understanding sufficient communicate intelligently investigator study coordinator , cooperate test examination require protocol . 5 . Subjects legal representative must consider reliable reporter . 6 . Each subject his/her authorized legal representative must understand nature study . The subject 's authorized legal representative must sign informed consent document subject must sign informed assent document ( ≥ 7 year old ) . 7 . Subject must able participate mandatory blood draw . 8 . Subject must able swallow pill . 9 . Subjects comorbid Oppositional Defiant Disorder ( ODD ) , Conduct Disorder ( CD ) , ObsessiveCompulsive Disorder ( OCD ) , Pervasive Developmental Disorder ( PDD ) , anxiety depressive disorder allow participate study provide meet exclusionary criterion . 10 . For concomitant therapy use treat ADHD , subject must stable dose medication 1 month prior study enrollment . The dose ADHD therapy change throughout duration study . 1 . Investigator his/her immediate family ; define investigator 's spouse , parent , child , grandparent , grandchild . 2 . Serious , unstable illness include hepatic , renal , gastroenterological , respiratory , cardiovascular ( include ischemic heart disease ) , endocrinologic , neurologic , immunologic , hematologic disease . 3 . Uncorrected hypothyroidism hyperthyroidism . 4 . Nonfebrile seizure without clear resolve etiology . 5 . DSMIV substance ( except nicotine caffeine ) dependence within past 6 month . 6 . Judged clinically serious suicidal risk . 7 . Any concomitant medication primary central nervous system activity specify Concomitant Medication portion protocol . 8 . Current diagnosis schizophrenia . 9 . Mental retardation ( IQ &lt; 75 ) . 10 . Pregnant nursing female . 11 . Known hypersensitivity Invega® similar formulation ( paliperidone , risperidone ) . 12 . A nonresponder history intolerance Invega® , treatment adequate dos determine clinician . 13 . Severe allergy multiple adverse drug reaction . 14 . Subjects hematological disorder . 15 . Subjects diabetes .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>bipolar disorder</keyword>
	<keyword>child</keyword>
	<keyword>adolescent</keyword>
	<keyword>Invega</keyword>
</DOC>